Janssen's Zytiga Shines At ASCO But Prostate Cancer Pipeline Progress May Dampen Impact

Janssen reported treatment altering Phase III data at ASCO 2017 for a new Zytiga combination targeting hormone-naïve metastatic prostate cancer patients – but the triple regimen's relevance might be short-lived as momentum builds in the late-stage pipeline.